BTK Inhibitor With CAR T-Cell Therapy Deemed Effective in Relapsed/Refractory MCL
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Diagnosis & Disease Information
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Bendamustine-Rituximab Induction Appears Effective in Mantle Cell Lymphoma
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Real-World Analysis Reveals Treatment, Survival Trends in Mantle Cell Lymphoma
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
Real-World Treatment Outcomes, Roles of Transplant and Maintenance Rituximab in Mantle Cell Lymphoma
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.
Ibrutinib Improves Upon Standard Care in Older Patients With Mantle Cell Lymphoma
Adding ibrutinib to standard chemoimmunotherapy improved the median progression-free survival by 2.3 years.
First-Line Ibrutinib With Rituximab May Be Effective in Elderly Patients With Mantle Cell Lymphoma
Researchers determined a combination of ibrutinib with rituximab appears to be effective in elderly patients with MCL.
Ibrutinib-Rituximab May Help Minimize Chemotherapy in Mantle Cell Lymphoma
The best overall response rate was 98%, and the complete response rate was 89%.
Incyte Withdraws Parsaclisib NDA for Follicular, Marginal Zone, and Mantle Cell Lymphomas
Incyte has withdrawn the NDA for parsaclisib for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...